Rosamond T. The high cost of cancer drugs and what we can do about it. Paper presented at: Mayo Clinic Proceedings; 2013.
Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Blood. 2013;121(22):4439-4442. doi:
10.1182/blood-2013-03-490003
Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists.
Health Affairs. 2010;29(1):196-202. doi:
10.1377/hlthaff.2009.0077
Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care.
J Clin Oncol. 2009;27(23):3868-3874. doi:
10.1200/jco.2009.23.1183
Marseille E, Larson B, Kazi DS, Kahnd JG, Rosenb S. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):65-132.
Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price.
J Clin Oncol. 2013;31(28):3600-3604. doi:
10.1200/jco.2013.49.1845
Bullock AJ, Hofstatter EW, Yushak ML, Buss MK. Understanding patients' attitudes toward communication about the cost of cancer care.
J Oncol Pract. 2012;8(4):e50-e58. doi:
10.1200/jop.2011.000418
Shih YCT, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?
CA: A Cancer Journal for Clinicians. 2008;58(4):231-244. doi:
10.3322/ca.2008.0008
Rouhollahi M, Mohamdnejad S, Harirchi I, et al. Recommendations for management of the Trastuzumab (Herceptin) among Iranian breast cancer patients, a policy brief. Basic & Clinical Cancer Research. 2014;6(2):27-34.
Hajizadeh M, Nghiem HS. Out-of-pocket expenditures for hospital care in Iran: who is at risk of incurring catastrophic payments?
Int J Health Care Finance Econ. 2011;11(4):267-285. doi:
10.1007/s10754-011-9099-1
Bazyar M, Pourreza A, Harirchi I, Akbari F, Mahmoudi M. Medical and non-medical direct costs of cancers in patients hospitalized in Imam Khomeini cancer institution - 2010. Hospital Journal. 2012;11 (1):39-50.
Alexander GC, Casalino LP, Tseng CW, McFadden D, Meltzer DO. Barriers to patient‐physician communication about out‐of‐pocket costs.
J Gen Intern Med. 2004;19(8):856-860. doi:
10.1111/j.1525-1497.2004.30249.x
Pouragha B, Pourreza A, Jaafaripooyan E, et al. The effect of access and out of pocket payment on the utilization of physicians services. World Appl Sci J. 2013;22(1):104-112.
Delavari H, Keshtkaran A, Setoudehzadeh F. Catastrophic health expenditures and coping strategies in households with cancer patients in Shiraz Namazi hospital. Middle East Journal of Cancer. 2014;5(1):13-22.
Ansaripour A, Uyl-de Groot CA, Steenhoek A, Redekop WK. The drug reimbursement decision-making system in Iran. Value in Health Regional Issues. 2014;3:174-181.
Drug Deputy of Iran Food and Drug Organization. The Drug Sales Statistics During 2014 (AmarNameh). Tehran, Iran: Ministry of Health and Medical Education; 2015.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Int J Cancer. 2015;136(5):E359-E386. doi:
10.1002/ijc.29210
Berry SR, Hubay S, Soibelman H, Martin DK. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
BMC Health Serv Res. 2007;7(1):193. doi:
10.1186/1472-6963-7-193
de Kort SJ, Kenny N, van Dijk P, Gevers S, Richel DJ, Willems DL. Cost issues in new disease-modifying treatments for advanced cancer: In-depth interviews with physicians.
Eur J Cancer. 2007;43(13):1983-1989. doi:
10.1016/j.ejca.2007.05.017
Berry SR, Bell CM, Ubel PA, et al. Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
J Clin Oncol. 2010;28(27):4149-4153. doi:
10.1200/jco.2010.29.1625
Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey.
J Clin Oncol. 2007;25(2):233-237. doi:
10.1200/jco.2006.09.2437
Thomson J, Schofield P, Mileshkin L, et al. Do oncologists discuss expensive anti-cancer drugs with their patients?
Ann Oncol. 2006;17(4):702-708. doi:
10.1093/annonc/mdj136
Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Oncologists’ and family physicians’ views on value for money of cancer and congestive heart failure care.
Isr J Health Policy Res. 2013;2:44. doi:
10.1186/2045-4015-2-44
Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States.
Cancer. 2010;116(14):3477-3484. doi:
10.1002/cncr.25150
Schnipper LE, Davidson NE, Wollins DS, et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options.
J Clin Oncol. 2015;33(23):2563-2577. doi:
10.1200/JCO.2015.61.6706
Kaser E, Shaw J, Marven M, Swinburne L, Boyle F. Communication about high-cost drugs in oncology—the patient view.
Ann Oncol. 2010;21(9):1910-1914. doi:
10.1093/annonc/mdq068
Henrikson NB, Tuzzio L, Loggers ET, Miyoshi J, Buist DS. Patient and oncologist discussions about cancer care costs.
Support Care Cancer. 2014;22(4):961-967. doi:
10.1007/s00520-013-2050-x
Hofstatter EW. Understanding patient perspectives on communication about the cost of cancer care: a review of the literature.
J Oncol Pract. 2010;6(4):188-192. doi:
10.1200/jop.777002
Irwin B, Kimmick G, Altomare I, et al. Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist. 2014;19(11):1135-1140.
Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence.
J Oncol Pract. 2014;10(3):162-167. doi:
10.1200/jop.2014.001406
Rosenberg-Yunger ZR, Thorsteinsdóttir H, Daar AS, Martin DK. Stakeholder involvement in expensive drug recommendation decisions: an international perspective.
Health Policy. 2012;105(2):226-235. doi:
10.1016/j.healthpol.2011.12.002
Pfister DG. The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution.
J Clin Oncol. 2013;31(28):3487-3489. doi:
10.1200/jco.2013.50.3466
Baradaran-Seyed Z, Nedjat S, Yazdizadeh B, Nedjat S, Majdzadeh R. Barriers of clinical practice guidelines development and implementation in developing countries: a case study in iran. Int J Prev Med. 2013;4(3):340.